Related Experiment Video
Updated: Jun 30, 2026

Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
CpG methylation is maintained in human cancer cells lacking DNMT1
1The Johns Hopkins Oncology Center, and Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
Abstract:
Hypermethylation is associated with the silencing of tumour susceptibility genes in several forms of cancer; however, the mechanisms responsible for this aberrant methylation are poorly understood. The prototypic DNA methyltransferase, DNMT1, has been widely assumed to be responsible for most of the methylation of the human genome, including the abnormal methylation found in cancers. To test this hypothesis, we disrupted the DNMT1 gene through homologous recombination in human colorectal carcinoma cells. Here we show that cells lacking DNMT1 exhibited markedly decreased cellular DNA methyltransferase activity, but there was only a 20% decrease in overall genomic methylation. Although juxtacentromeric satellites became significantly demethylated, most of the loci that we analysed, including the tumour suppressor gene p16INK4a, remained fully methylated and silenced. These results indicate that DNMT1 has an unsuspected degree of regional specificity in human cells and that methylating activities other than DNMT1 can maintain the methylation of most of the genome.
Insights
DNA methyltransferase 1 (DNMT1) is not solely responsible for genomic methylation in human cancer cells. Other enzymes maintain methylation, indicating DNMT1 has regional specificity.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Aberrant DNA methylation, particularly hypermethylation, is a hallmark of cancer, often leading to the silencing of tumor suppressor genes.
- The precise mechanisms driving this abnormal methylation are not fully understood, with DNA methyltransferase 1 (DNMT1) being the presumed primary enzyme responsible for genomic methylation.
Purpose of the Study:
- To investigate the role of DNMT1 in maintaining global genomic methylation and specific gene methylation in human colorectal carcinoma cells.
- To determine if DNMT1 is the sole enzyme responsible for aberrant methylation in cancer.
Main Methods:
- Disruption of the DNMT1 gene in human colorectal carcinoma cells using homologous recombination.
- Measurement of cellular DNA methyltransferase activity.
- Analysis of overall genomic methylation levels.
- Assessment of methylation status at specific loci, including juxtacentromeric satellites and the p16INK4a tumor suppressor gene.
Main Results:
- Cells lacking DNMT1 showed significantly reduced cellular DNA methyltransferase activity.
- Overall genomic methylation decreased by only 20% in DNMT1-deficient cells.
- Juxtacentromeric satellite regions were significantly demethylated, but most analyzed loci, including p16INK4a, remained fully methylated and silenced.
- These findings suggest the presence of alternative methylating activities in human cells.
Conclusions:
- DNMT1 exhibits unexpected regional specificity in its methylation activity within human cells.
- Enzymes other than DNMT1 play a crucial role in maintaining the methylation status of the majority of the human genome, even in the context of cancer.
Related Concept Videos
Epigenetic Regulation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Induced Pluripotent Stem Cells
Somatic cells are...
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

